Hold On to Your Hair: 3 Leading Treatments for Male Pattern Baldness

Men, the odds are stacked against you.

By age 35, around two-thirds of all American men will have begun to experience androgenetic alopecia, more commonly known as male pattern baldness. By age 50, around 85% of men have significantly thinning hair. For nearly a quarter of American men, the onset of male pattern baldness hits before they're age 21.

What options are available for those men who don't want to yield any ground on their heads to baldness? Some take the toupee approach. Others go for hair transplants. Many, though, instead opt for medications that promise to improve their odds of keeping and sometimes even regrowing hair. Here are three of the top treatments in this category.

First introduced back in 1988 by Upjohn, Rogaine is the granddaddy of male pattern baldness drugs. Johnson & Johnson acquired rights to the product in 2006 and soon afterward launched Rogaine Foam. After all these years, Rogaine still stands as the most recommended brand for hair regrowth by dermatologists.

The active ingredient in Rogaine, minoxidil, was initially developed to treat high blood pressure. However, researchers noticed an intriguing side effect of the drug -- hair regrowth. Minoxidil works by increasing the size of hair follicles, according to J&J. The Mayo Clinic, on the other hand, says that exactly how the drug works remains unknown.

Rogaine is available over-the-counter (including in generic form) and does work for many men. J&J reports clinical studies that found almost nine out of 10 men using Rogaine Foam regrew hair after four months of taking the product. However, one of the relatively rare side effects is actually increased loss of hair. J&J notes that men typically shed hair during early usage of Rogaine, but that the hair "usually" begins to regrow after several months. For some men, that regrowth doesn't occur.

Merck made $427 million in 2012 from male pattern baldness prescription drug Propecia. The drug, known generically as finasteride, is also sold under the brand name Proscar as a treatment for benign prostatic hyperplasia in men with an enlarged prostate.

Propecia works by preventing conversion of testosterone to dihydrotestosterone, or DHT. Decreasing levels of DHT on the scalp appears to help prevent the shrinking of hair follicles. Studies have found that 90% of men with mild to moderate hair loss who took Propecia showed some visible results after five years  -- 48% experienced regrowth of hair and 42% had no further hair loss.

These good results make Propecia a good choice for many men who want to hold on to their hair. However, a small number (less than 2%) experience sexual side effects, including decreased libido. In 2012, the Food and Drug Administration required Merck to explain that some of these potential side effects could continue even after discontinuing usage of the drug.

While it's not officially available as a treatment for baldness, some physicians prescribe Avodart off-label for patients wanting to regrow hair. GlaxoSmithKline markets the drug for treating benign prostatic hyperplasia. The company reported 2012 sales of around $1.2 billion for its Avodart franchise, but how much of that total was prescribed for male pattern baldness is unknown.

Like Propencia, Avodart works by lowering levels of DHT. One key difference is that Avodart inhibits all three isoforms of the enzyme critical in reducing DHT, while Propencia inhibits only two of the isoforms. Glaxo completed a late-stage South Korean clinical study for the drug as a treatment for male pattern baldness in 2009. The study found that Avodart significantly improved hair growth, but the company has not announced any intentions to move forward with seeking regulatory approval for the indication.

The most common side effects of Avodart include impotence and lowered libido. A more serious adverse effect can be a higher likelihood of prostate cancer.

On the way?
Of course, there are other products that are used as hair loss treatments -- some effective and some not so much. Better yet, more could be on the way. 

Researchers at the University of Pennsylvania discovered a link between a protein called prostaglandin D synthase, or PGD2, and baldness. The team of scientists developed a PGD2-inhibiting pill and hope to also create a cream version. Clinical trials could begin within the next couple of years.

Then there's bimatoprost from Allergan . Allergan first developed and marketed the drug to help individuals grow eyelashes. In May, the company announced disappointing phase 2 results for bimatoprost as a treatment for baldness. However, Allergan plans to move ahead with testing using a much stronger formulation.

While the odds are stacked against men with respect to baldness for now, current treatments can help. Future treatments could help even more. In the meantime, just keep holding on.

Even those who aren't concerned about male pattern baldness could be tempted to pull out their hair after seeing their tax bills. Tax increases that took effect at the beginning of 2013 affected nearly every American taxpayer. But with the right planning, you can take steps to take control of your taxes and potentially even lower your tax bill.

In our brand-new special report "How You Can Fight Back Against Higher Taxes," The Motley Fool's tax experts run through what to watch out for in doing your tax planning this year. With its concrete advice on how to cut taxes for decades to come, you won't want to miss out. Click here to get your copy today -- it's absolutely free.

The article Hold On to Your Hair: 3 Leading Treatments for Male Pattern Baldness originally appeared on Fool.com.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story